The Category 2 Ban and the 2026 Reclassification In 2023, the FDA pulled 19 of the most popular peptides BPC-157, TB-500, CJC-1295, among others off the compounding-permitted list and placed them on the restricted Category 2 list, citing safety concerns, impurity issues, and a lack of clinical data
My health and vitality have improved significantly
No controlled human trial has validated a topical AHK-Cu concentration or schedule
I often recommend them as part of a broader plan that includes spinal correction and lifestyle adjustments
I have personally used it for acute injuries and have found it effective, particularly when the injury involves soft tissue rather than advanced joint degeneration
No side effects were observed, and daytime alertness was consistent [4]